Whoops-Resections – how can we improve?

Jost, Rahel; Müller, Daniel A.; Lese, Iona; Brodmann, Stefan; Digklia, Antonia; Rothermundt, Christian; Kollár, Attila (2023). Whoops-Resections – how can we improve? info@onco-suisse(3), pp. 16-19. Aerzteverlag medinfo AG

Text 16_19_onco_03_FB_Kollar_Jost_Whoops.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (306kB)

Soft tissue sarcomas (STS) are a rare and heterogeneous group of
malignant tumors of mesenchymal origin that comprise less than
1 percent of all adult malignancies and approximately 12 percent of
pediatric cancers. The age-standardized incidence rate in Switzerland
is 4.43 per 100,000 person-years for STS. Sarcomas occur at all anatomic body sites, but the majority are in the extremities (Fig.1) (1).
Due to their rarity, STSs are often not considered in the differential diagnosis. Often, STS presents as a slowly enlarging, superficial,
soft-tissue lesion, sometimes following a history of trauma. Given
the much higher frequency of benign soft-tissue lesions, STSs are
often treated surgically as unplanned excisions (UE). Hence, excision is performed without previous imaging and biopsy, without
adherence to a proper diagnostic pathway and therapeutic plan. As
both the surgeon and the patient are astonished to note the pathological finding of a supposedly benign lesion as "malignant", the
surgery performed is referred to as a "Whoops resection". Consecutively, micro- or even macroscopically residual tumor might persist
in the surgical situs, potentially requiring second and maybe more extensive surgery (including amputation). As a result, UE might
lead to increased functional disabilities and therefore reduced
quality of life with a relevant impact on daily living. Importantly,
UE might be associated with increased local recurrence rates and
decreased survival (2).
The rates of whoops resections reported in the literature vary from
approximately 11.3% to over half of STS resections (3). While there
appears to be no association with patient residence and insurance
status, UE rates are lower in tertiary centers than in non-tertiary
hospitals. Notably, these rates highly depend on the country-specific structure and collaboration within sarcoma networks and
referral patterns.
According to current guidelines, biopsy-proven STS requires a wide
surgical resection as an essential treatment for virtually all patients.
Depending on patient and tumor characteristics, perioperative
radiation- and/or chemotherapy should be considered in order to
improve patient outcome.
This review aims to raise awareness for this clinically relevant topic,
discuss the impact of UE on patient quality of life and treatment
outcomes, and provide guidance for future improvements

Interest & Impact

Downloads

1 since deposited on 23 Dec 2023
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item